Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUARD-1: Semaglutide in Patients Receiving Maintenance Dialysis
NCT07017270Phase 4Recruiting
- Sponsor
- Unity Health Toronto
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Unity Health Toronto. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07017270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017270.